{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:18:32Z","timestamp":1768713512209,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2016.11.078","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T01:48:34Z","timestamp":1493257714000},"page":"3143-3151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost effectiveness of a targeted age-based West Nile virus vaccination program"],"prefix":"10.1016","volume":"35","author":[{"given":"Manjunath B.","family":"Shankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Erin","family":"Staples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin I.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.11.078_b0005","series-title":"Red book: 2015 report of the committee on infectious diseases","first-page":"865","article-title":"West Nile Virus","author":"American Academy of Pediatrics","year":"2015"},{"issue":"14","key":"10.1016\/j.vaccine.2016.11.078_b0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMp1210537","article-title":"Unpredictable and difficult to control\u2013the adolescence of West Nile virus","volume":"367","author":"Petersen","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.11.078_b0015","first-page":"1","article-title":"Surveillance for human West Nile virus disease \u2013 United States, 1999\u20132008","volume":"59","author":"Lindsey","year":"2010","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2016.11.078_b0020","unstructured":"Centers for Disease Control and Prevention. West Nile virus statistics and maps; Available from: <http:\/\/www.cdc.gov\/westnile\/statsMaps\/> [Accessed 2015 October 26]."},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.078_b0025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.13-0206","article-title":"Initial and long-term costs of patients hospitalized with West Nile virus disease","volume":"90","author":"Staples","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"24","key":"10.1016\/j.vaccine.2016.11.078_b0030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM200106143442401","article-title":"The outbreak of West Nile virus infection in the New York City area in 1999","volume":"344","author":"Nash","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.078_b0035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3201\/eid1205.051287","article-title":"West Nile virus infections projected from blood donor screening data, United States, 2003","volume":"12","author":"Busch","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2016.11.078_b0040","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3201\/eid1804.111313","article-title":"Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999\u20132008","volume":"18","author":"Carson","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.078_b0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.2013.8042","article-title":"West Nile virus: review of the literature","volume":"310","author":"Petersen","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2016.11.078_b0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/rmv.501","article-title":"Manifestations of West Nile neuroinvasive disease","volume":"16","author":"Sejvar","year":"2006","journal-title":"Rev Med Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.11.078_b0055","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3278","article-title":"West Nile virus disease in children, United States, 1999\u20132007","volume":"123","author":"Lindsey","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.11.078_b0060","unstructured":"Centers for Disease Control and Prevention. West Nile Virus in the United States: guidelines for surveillance, prevention, and control. Available from: <http:\/\/www.cdc.gov\/westnile\/resources\/pdfs\/wnvGuidelines.pdf> [Accessed 2015 October 26]."},{"issue":"5","key":"10.1016\/j.vaccine.2016.11.078_b0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3201\/eid1405.071347","article-title":"Efficacy of aerial spraying of mosquito adulticide in reducing incidence of West Nile Virus, California, 2005","volume":"14","author":"Carney","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2016.11.078_b0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.4269\/ajtmh.2012.11-0502","article-title":"Modifiable risk factors for West Nile virus infection during an outbreak\u2013Arizona, 2010","volume":"86","author":"Gibney","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2016.11.078_b0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2016.11.078_b0080","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u2a7e50 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.078_b0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1297-9716-43-16","article-title":"Recent progress in West Nile virus diagnosis and vaccination","volume":"43","author":"De Filette","year":"2012","journal-title":"Vet Res"},{"issue":"48","key":"10.1016\/j.vaccine.2016.11.078_b0090","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.078_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3201\/eid1203.050782","article-title":"Cost-effectiveness of West Nile virus vaccination","volume":"12","author":"Zohrabian","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"27","key":"10.1016\/j.vaccine.2016.11.078_b0100","first-page":"269","article-title":"Vaccines and vaccination against yellow fever. WHO position paper \u2013 June 2013","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"issue":"15","key":"10.1016\/j.vaccine.2016.11.078_b0105","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.vaccine.2012.02.005","article-title":"Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine","volume":"30","author":"Desai","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.078_b0110","series-title":"Prevention effectiveness: a guide to decision analysis and economic evaluation","author":"Haddix","year":"2003"},{"key":"10.1016\/j.vaccine.2016.11.078_b0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1749-6632.2001.tb02706.x","article-title":"West Nile virus serosurvey and assessment of personal prevention efforts in an area with intense epizootic activity: Connecticut, 2000","volume":"951","author":"McCarthy","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2016.11.078_b0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-3-18","article-title":"Values for preventing influenza-related morbidity and vaccine adverse events in children","volume":"3","author":"Prosser","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vaccine.2016.11.078_b0125","series-title":"Vaccines","first-page":"870","article-title":"Yellow fever vaccine","author":"Monath","year":"2013"},{"key":"10.1016\/j.vaccine.2016.11.078_b0130","unstructured":"Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. In: National vital statistics reports. 2010, vol. 58(19), National Center for Health Statistics: Hyattsville, MD."},{"issue":"6","key":"10.1016\/j.vaccine.2016.11.078_b0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/506939","article-title":"Long-term clinical and neuropsychological outcomes of West Nile virus infection","volume":"43","author":"Carson","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"9278","key":"10.1016\/j.vaccine.2016.11.078_b0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0140-6736(01)05480-0","article-title":"Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey","volume":"358","author":"Mostashari","year":"2001","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2016.11.078_b0145","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1086\/656602","article-title":"West Nile fever characteristics among viremic persons identified through blood donor screening","volume":"202","author":"Zou","year":"2010","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2016.11.078_b0150","doi-asserted-by":"crossref","DOI":"10.2105\/AJPH.2012.300651","article-title":"Self-reported influenza-like illness and receipt of influenza antiviral drugs during the 2009 pandemic, United States, 2009\u20132010","volume":"102","author":"Biggerstaff","year":"2012","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2016.11.078_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/infdis\/jiu224","article-title":"Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010\u20132011 influenza season-United States","volume":"210","author":"Biggerstaff","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2016.11.078_b0160","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2105\/AJPH.2012.300799","article-title":"Seasonal influenza morbidity estimates obtained from telephone surveys, 2007","volume":"103","author":"Kamimoto","year":"2013","journal-title":"Am J Public Health"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2016.11.078_b0165","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1348\/174866407X218312","article-title":"Neurocognitive and functional outcomes in persons recovering from West Nile virus illness","volume":"2","author":"Sejvar","year":"2008","journal-title":"J Neuropsychol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.078_b0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3201\/eid1603.090667","article-title":"Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005","volume":"16","author":"Barber","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2016.11.078_b0175","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.11.078_b0180","unstructured":"Centers for Disease Control and Prevention. CDC vaccine price list. Available from: <http:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/> [Accessed 2015 October 2015]."},{"issue":"48","key":"10.1016\/j.vaccine.2016.11.078_b0185","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.078_b0190","unstructured":"Institute of Medicine. Vaccines for the 21st Century: a tool for decision making. Stratton KR, Durch JS, Lawrence RS, editors. Committee to study priorities for vaccine development, division of health promotion and disease prevention. Washington D.C.: National Academies Press; 2000."},{"issue":"5","key":"10.1016\/j.vaccine.2016.11.078_b0195","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-141-5-200409070-00010","article-title":"Clinical characteristics and functional outcomes of West Nile Fever","volume":"141","author":"Watson","year":"2004","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2016.11.078_b0200","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.4161\/hv.28670","article-title":"Cost-effectiveness of vaccination against herpes zoster","volume":"10","author":"de Boer","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2016.11.078_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.7326\/0003-4819-143-7-200510040-00007","article-title":"The cost-effectiveness of screening the U.S. blood supply for West Nile virus","volume":"143","author":"Custer","year":"2005","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.11.078_b0210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/506570","article-title":"Blood screening for West Nile virus: the cost-effectiveness of a real-time, trigger-based strategy","volume":"43","author":"Korves","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2016.11.078_b0215","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0030021","article-title":"Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States","volume":"3","author":"Korves","year":"2006","journal-title":"PLoS Med"},{"issue":"03","key":"10.1016\/j.vaccine.2016.11.078_b0220","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"Petersen","year":"2013","journal-title":"Epidemiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T09:51:51Z","timestamp":1535881911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16311495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":44,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X16311495"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost effectiveness of a targeted age-based West Nile virus vaccination program","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}